We have identified miR29, which targets T-bet and interferon gamma (IFNγ), as important to study in MS. We reasoned that MS patients might have altered levels of miR 29 and indeed found that purified CD4+ T cells from MS patients had lower basal levels of miR-29 relative to control patients.